Feed CYBQF
Summary
39 / 100 · Bulios Score
Valuation 28Growth 80Profitability 30Quality 3Debt 69Stability 37
What speaks for it
- Revenue grew by 27% a year over the last 3 years.
- It holds more cash than debt: ¥13.0B against ¥536.1M.
What to watch
- It reports a profit, yet spends more cash than it brings in.
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveP/E today 107.3
Medical - Devices industry median
Today you pay 107.3 JPY for 1 JPY of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (JPY)
2021202220232024202520262027
Diluted EPS (JPY)
2021202220232024202520262027
- Analyst estimate
Revenue grew by 20% a year over 5 years. Over the last 3 years it grew by 27% a year.
Growth in detailDoes it make money?
PoorlyWhere 100 JPY of revenue goes
- Cost of sales 51 JPY
- Research and development 25 JPY
- Sales and administration 52 JPY
- Taxes and other -34 JPY
- Net profit 7.0 JPY
Net profit, industry median (Medical - Devices) 6.9 JPY
Out of every 100 JPY of revenue, 7.0 JPY is left as net profit.
Profitability in detailIs it financially healthy?
YesCash and short-term investments ¥13.0B
Debt ¥536.1M
Free cash flow over 12 months -¥119.6M
Over the last 12 months it spent more cash than it brought in. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.